Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
- Dondorp, Arjen M
- Fanello, Caterina I
- Hendriksen, Ilse CE
- Gomes, Ermelinda
- Seni, Amir
- Chhaganlal, Kajal D
- Bojang, Kalifa
- Olaosebikan, Rasaq
- Anunobi, Nkechinyere
- Maitland, Kathryn
- Kivaya, Esther
- Agbenyega, Tsiri
- Nguah, Samuel Blay
- Evans, Jennifer
- Gesase, Samwel
- Kahabuka, Catherine
- Mtove, George
- Nadjm, Behzad
- Deen, Jacqueline
- Mwanga-Amumpaire, Juliet
- Nansumba, Margaret
- Karema, Corine
- Umulisa, Noella
- Uwimana, Aline
- Mokuolu, Olugbenga A
- Adedoyin, Olanrewaju T
- Johnson, Wahab BR
- Tshefu, Antoinette K
- Onyamboko, Marie A
- Sakulthaew, Tharisara
- Ngum, Wirichada Pan
- Silamut, Kamolrat
- Stepniewska, Kasia
- Woodrow, Charles J
- Bethell, Delia
- Wills, Bridget
- Oneko, Martina
- Peto, Tim E
- von Seidlein, Lorenz
- Day, Nicholas PJ
- White, Nicholas J
DOIAbstract
SummaryBackgroundSevere malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate or quinine in African children with severe malaria.MethodsThis open-label, randomised trial was undertaken in 11 centres in nine African countries. Children (<15 years) with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine. Randomisation was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper en...
Add to ORKG